Introduction
Primary bone lymphoma (PBL) is a rare clinical entity accounting for <1% of all malignant lymphomas and 7% of all malignant bone tumors. According to the WHO, PBL is defined as a tumor composed of malignant lymphoid cells, producing one or more masses within bone, without any supraregional lymph node involvement or other extranodal lesions. B-cell lymphoblastic lymphoma (LBL) with primary bone involvement is infrequently reported in literature, and data regarding this condition are limited.

We report two children with this condition.

Case Report
Case 1
A 2-year-old girl presented in 2014 with pain of the right thigh of 3-week duration. Local examination revealed tenderness of the distal end of the femur without any swelling or lymphadenopathy. Systemic examination was normal. Her hemogram was normal and lactate dehydrogenase (LDH) level was 569 U/L. Radiographs showed an irregular lytic lesion involving the distal metadiaphyseal region of the right femur [Figure 1]. Magnetic resonance imaging (MRI) revealed a marrow infiltrative expansile lesion with cortical erosion and thinning [Figure 2]. Bone scan showed abnormally increased localization at the primary site. Bone biopsy revealed sheets of small round cells which were positive for leukocyte common antigen (LCA), terminal deoxynucleotidyl transferase (TdT), CD10, CD20 and weakly positive for CD99 [Figure 3]. Chromogranin, synaptophysin, CD3, CD5 and MPO were negative. The patient was diagnosed to have precursor B-cell LBL of the femur. Bone marrow and cerebrospinal fluid (CSF) studies were normal. She has completed chemotherapy according to the modified Berlin-Frankfurt-Münster acute lymphoblastic leukemia high-risk protocol. She shows good response and remains free of any recurrence.

Case 2
A 7-year-old girl presented in 2006 with a 2-month history of pain of the right leg after trivial trauma. The physical examination, hemogram and LDH levels were normal. An ill-defined lytic lesion was seen on X-ray in the proximal diaphyseal region of the right tibia, extending into the epiphysis with minimal periosteal and soft-tissue reaction. There was cortical thinning and haziness of the endosteum suggestive of a malignant lesion. She was referred to us as a case of Ewing’s sarcoma.

Abstract
Precursor B-cell lymphoblastic lymphoma (LBL) occurring as a primary bone tumor is a rare clinical presentation in children, and data regarding this condition are limited to small case series or a few individual case reports. We report two pediatric cases of precursor B-cell LBL of the bone. The tumor cells from bone biopsies of both patients were seen to be positive for leukocyte common antigen (LCA), terminal deoxynucleotidyl transferase, CD10, CD20 and weakly positive for CD99. Bone marrow studies were normal. They were treated according to the modified Berlin-Frankfurt-Münster acute lymphoblastic leukemia high-risk protocol. The first patient has completed treatment including local radiotherapy and has been disease free for the past 10 years. The second patient has recently completed treatment and shows good response.

Keywords: Bone tumors, lymphoblastic lymphoma, pediatric oncology, primary bone lymphoma

How to cite this article: Seetharam S, Thankamony P, Jacob PM, Nair RA. Precursor B-cell lymphoblastic lymphoma of bone in children: A close mimicker of Ewing's sarcoma. Indian J Med Paediatr Oncol 2018;39:385-7.

Address for correspondence:
Dr. Priyakumari Thankamony,
Division of Pediatric Oncology,
Regional Cancer Centre,
Thiruvananthapuram - 695 011,
Kerala, India.
E-mail: drpriyarcc@gmail.com

Access this article online
Website: www.ijmpo.org
DOI: 10.4103/ijmpo.ijmpo_149_16
Seetharam, et al.: Precursor B-cell lymphoblastic lymphoma of bone

A bone biopsy showed small cleaved lymphoid cells with immature chromatin. The tumor cells were positive for LCA, TdT, CD20, CD10 and CD99 and negative for CD3 and CD5. CSF and bone marrow biopsy were normal. She was diagnosed with precursor B-cell LBL of the bone and treated with chemotherapy according to the institutional ALL protocol for 2½ years along with local radiotherapy (35 Gy in 20 fractions). She remains disease free for the past 10 years.

**Discussion**

PBL is a rare entity of which 70% are diffuse large B-cell lymphomas. It is infrequent for a LBL to present as a PBL.\(^4\) LBL occurs more often in children than in adults and occurs mostly in males.\(^3\) It constitutes about 20% of childhood non-Hodgkin’s lymphoma (NHL) and is predominantly of the precursor T-cell type.\(^4\) Precursor B-cell LBL is a rare entity and accounts for only 3% of pediatric NHL.\(^7\) Patients with B-cell LBL often have limited stage disease which may involve isolated node or rarely skin or bone. Patients with bone involvement may present with complaints of pain and/or a palpable swelling.

PBL typically presents as a solitary, permeative, metadiaphyseal lesion in a long bone with layered periosteal reaction and minimal cortical destruction. The femur is most commonly involved.\(^2,4\) Radiologically, the tumor may resemble osteosarcoma, Ewing’s sarcoma, neuroblastoma metastasis or Langerhans cell histiocytosis. MRI is very helpful in evaluating the bone marrow involvement, associated soft-tissue masses and early detection of cortical erosion.

Precursor B-cell LBL may mimic Ewing’s sarcoma (ES) which is the second most common primary bone malignancy in pediatrics and the most common round cell tumor involving the bone.\(^4\) It is of vital importance to distinguish B-cell LBL from ES as the clinical behavior, treatment and outcome differ significantly. The tumor cells in both conditions are uniform and small and have a diffuse and infiltrative growth pattern. Other differential diagnoses include small round cell tumors such as neuroblastoma metastasizing to bone, small cell osteogenic sarcoma, desmoplastic small round cell tumor and myeloid sarcoma.

Immunohistochemically, only two-thirds of LBLs express LCA while CD99 expression, which was believed to be specific for ES, is seen in up to 75% patients with LBL.\(^8\) Therefore, the probability of misdiagnosing an LCA-negative, CD99-positive tumor as ES is considerable when a limited immunohistochemical (IHC) panel is used. TdT has been found to be the best discriminator of LBL and ES [Table 1]. In addition, ES has characteristic cytogenetic and molecular genetic findings (most commonly \(t\) (11;22) with EWS/FLI-1 fusion) which are helpful in confirming the diagnosis. Due to technical limitations and financial constraints, molecular confirmation was not done in both of our patients. However, the diagnosis could be confirmed with the extended IHC panel.
The current standard treatment for LBL is based on the multidrug chemotherapy protocols for leukemia.\(^9\) Radiotherapy also played a significant role in treatment regimens in the past, both as a single modality and in combination with chemotherapy. However, radiation is associated with an increased risk of secondary malignancies in the radiation field as reported in patients with PBL who later developed sarcomas.\(^9\) As various studies have shown favorable survival rates without radiation, this modality is no longer included in standard treatment plans.\(^9\) Our patient treated in 2014 did not receive any form of local therapy and has shown good response with chemotherapy alone while the child treated in 2006 received local radiotherapy along with systemic chemotherapy. Both patients remain free of any recurrence.

To conclude, precursor B-cell LBL of the bone is a rare occurrence which presents in children as bone pain with an associated lytic bone lesion. It can mimic ES both clinically and immunohistochemically. These children have excellent outcome when treated with multidrug chemotherapy regimens as used in leukemia. Adjunctive radiation is no longer considered necessary in the definitive treatment. Though rare, this condition may be considered in the differential diagnosis when dealing with small round cell tumors of the bone in children.

### Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### Table 1: Differences in the immunophenotypic profile of lymphoblastic lymphoma and Ewing’s sarcoma

<table>
<thead>
<tr>
<th>Ancillary test</th>
<th>LBL</th>
<th>ES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunohistochemistry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TdT</td>
<td>Positive in 92% cases</td>
<td>Negative</td>
</tr>
<tr>
<td>LCA (CD45)</td>
<td>Usually positive (62%)</td>
<td>Negative</td>
</tr>
<tr>
<td>CD99</td>
<td>Positive in 75% cases (weak membrane positivity)</td>
<td>Cytoplasmic and membrane pattern of positivity</td>
</tr>
<tr>
<td>Molecular characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EWS-FL1 fusion transcript</td>
<td>Negative</td>
<td>Positive in 85% cases</td>
</tr>
<tr>
<td>PCR for Ig heavy chain rearrangement</td>
<td>Positive in 90% cases</td>
<td>Negative</td>
</tr>
</tbody>
</table>

TdT – Terminal deoxynucleotidyl transferase; LCA – Leukocyte common antigen; CD – Cluster differentiation; PCR – Polymerase chain reaction; ES – Ewing’s sarcoma; LBL – Lymphoblastic lymphoma

### References